Title |
Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial
|
---|---|
Published in |
Trials, May 2014
|
DOI | 10.1186/1745-6215-15-160 |
Pubmed ID | |
Authors |
Nathan R Hill, Daniel Lasserson, Ben Thompson, Rafael Perera-Salazar, Jane Wolstenholme, Peter Bower, Thomas Blakeman, David Fitzmaurice, Paul Little, Gene Feder, Nadeem Qureshi, Maarten Taal, Jonathan Townend, Charles Ferro, Richard McManus, FD Richard Hobbs |
Abstract |
Chronic kidney disease (CKD) is common and increasing in prevalence. Cardiovascular disease (CVD) is a major cause of morbidity and death in CKD, though of a different phenotype to the general CVD population. Few therapies have proved effective in modifying the increased CVD risk or rate of renal decline in CKD. There are accumulating data that aldosterone receptor antagonists (ARA) may offer cardio-protection and delay renal impairment in patients with the CV phenotype in CKD. The use of ARA in CKD has therefore been increasingly advocated. However, no large study of ARA with renal or CVD outcomes is underway. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 2% |
Unknown | 64 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 10 | 15% |
Student > Master | 7 | 11% |
Researcher | 6 | 9% |
Student > Ph. D. Student | 5 | 8% |
Student > Doctoral Student | 4 | 6% |
Other | 11 | 17% |
Unknown | 22 | 34% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 22 | 34% |
Nursing and Health Professions | 9 | 14% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
Psychology | 2 | 3% |
Agricultural and Biological Sciences | 1 | 2% |
Other | 5 | 8% |
Unknown | 24 | 37% |